{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:42:33Z","timestamp":1794008553004,"version":"4.8.0"},"reference-count":133,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016747","name":"Mercer University","doi-asserted-by":"crossref","award":["DG00310"],"award-info":[{"award-number":["DG00310"]}],"id":[{"id":"10.13039\/100016747","id-type":"DOI","asserted-by":"crossref"}]},{"award":["DG00310"],"award-info":[{"award-number":["DG00310"]}],"id":[{"id":"https:\/\/ror.org\/01g67by91","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Empowered by nanotechnology, messenger RNA (mRNA) therapeutics have shown a rapid evolution post COVID-19 from a conceptual platform to a clinically validated modality, and they diversified into oncology, cardiovascular diseases, and rare disorders. As a template for in situ protein production, it offers several advantages over traditional proteins and DNA drugs. The intrinsic stability of mRNA and its sensitivity to innate immune sensing hinder its capacity for immediate cellular entry, necessitating its need for a delivery system to obtain optimal therapeutic potential. This review explores the innovations in nanocarrier engineering, design principles for lipid nanoparticles-mRNA (LNPs) platforms, and their clinical translation across the prominent indications. It also addresses their safety, immunogenicity, and scalability while addressing the key limitations and manufacturing scalability through comparative platform analysis. Although LNPs usually dominate their delivery through encapsulation and manufacturability, their limitations, like repeat dose reactogenicity and liver tropism, require next-generation designs like SORT lipids, stimuli-responsive hybrids for extrahepatic targeting. In oncology, LNP-mRNA drives the neoantigen vaccines, and rare diseases leverage the transient enzyme replacement. While the safety profiles highlight the innate immune tuning through nucleoside mods and lipid biodegradability, chronic administration risks are still persistent. While there are novel scalability options like microfluidic mixing to support the production gaps in organ selectivity and durability, their adoption is hindered. We outline the future directions to perceive mRNA\u2019s full potential as a broader therapeutic class.<\/jats:p>","DOI":"10.3390\/ph19050663","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T17:26:18Z","timestamp":1777051578000},"page":"663","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Delivery of mRNA Therapeutics Beyond Infectious Diseases: Design Innovations and Applications in Oncology, Cardiovascular, and Rare Genetic Diseases"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6584-2678","authenticated-orcid":false,"given":"Snehitha","family":"Akkineni","sequence":"first","affiliation":[{"name":"College of Pharmacy, Mercer University, Atlanta, GA 30341, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahek","family":"Gulani","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Mercer University, Atlanta, GA 30341, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir A.","family":"Kouzi","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Wingate University, Wingate, NC 28174, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"D\u2019Souza","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Mercer University, Atlanta, GA 30341, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1986-6544","authenticated-orcid":false,"given":"Mohammad N.","family":"Uddin","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Mercer University, Atlanta, GA 30341, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1021\/acs.molpharmaceut.3c00439","article-title":"Complex Coacervates as a Promising Vehicle for mRNA Delivery: A Comprehensive Review of Recent Advances and Challenges","volume":"20","author":"Forenzo","year":"2023","journal-title":"Mol. Pharm."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"103839","DOI":"10.1016\/j.jddst.2022.103839","article-title":"An insight on lipid nanoparticles for therapeutic proteins delivery","volume":"77","author":"Viegas","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"114416","DOI":"10.1016\/j.addr.2022.114416","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","volume":"188","author":"Kulkarni","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1038\/s41591-022-02061-1","article-title":"The landscape of mRNA nanomedicine","volume":"28","author":"Huang","year":"2022","journal-title":"Nat. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Yadav, N., Debnath, N., and Das, S. (2026). Stimuli-responsive nanocarriers for targeted mRNA therapeutics: A paradigm shift in mRNA delivery for biomedical applications. Drug Deliv. Transl. Res.","DOI":"10.1007\/s13346-025-02040-2"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/jpp\/rgad089","article-title":"Engineering carrier nanoparticles with biomimetic moieties for improved intracellular targeted delivery of mRNA therapeutics and vaccines","volume":"76","author":"Puccetti","year":"2024","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Ahl, P.L. (2025). Microfluidic and Turbulent Mixing for mRNA LNP Vaccines. Pharmaceutics, 17.","DOI":"10.20944\/preprints202507.1723.v2"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"6820","DOI":"10.1039\/D4NR00019F","article-title":"Advances in lipid nanoparticle mRNA therapeutics beyond COVID-19 vaccines","volume":"16","author":"Wu","year":"2024","journal-title":"Nanoscale"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1016\/j.ymthe.2025.04.044","article-title":"Therapeutic mRNA vaccine applications in oncology","volume":"33","author":"Elliott","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s12672-025-03070-5","article-title":"mRNA vaccines and SiRNAs targeting cancer immunotherapy: Challenges and opportunities","volume":"16","author":"Lv","year":"2025","journal-title":"Discov. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Gawalski, K., Przybyszewska, W., Hunia, J., Gawalska, A., and Rymarz, A. (2025). Unraveling the potential: mRNA therapeutics in oncology. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1643444"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1039\/D5PM00079C","article-title":"A new strategy for the extrahepatic delivery of lipid-based nanomedicines: A protein corona-mediated selective targeting system based on an ionizable cationic lipid library","volume":"2","author":"Younis","year":"2025","journal-title":"RSC Pharm."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Fang, Z., Monteiro, V.S., Oh, C., Janabi, K.A., Romero, L., Ahsan, N., Yang, L., Peng, L., DiMaio, D., and Lucas, C. (2025). A modular vaccine platform for optimized lipid nanoparticle mRNA immunogenicity. Nat. Biomed. Eng.","DOI":"10.1038\/s41551-025-01478-6"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Abughalia, A., Flynn, M., Clarke, P.F.A., Fayne, D., and Gobbo, O.L. (2025). The Use of Computational Approaches to Design Nanodelivery Systems. Nanomaterials, 15.","DOI":"10.3390\/nano15171354"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1152\/physiol.00047.2024","article-title":"Harnessing Computational Strategies to Overcome Challenges in mRNA Vaccines","volume":"40","author":"Zhao","year":"2025","journal-title":"Physiology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e70414","DOI":"10.1002\/mco2.70414","article-title":"Design Strategies for Novel Lipid Nanoparticle for mRNA Vaccine and Therapeutics: Current Understandings and Future Perspectives","volume":"6","author":"Li","year":"2025","journal-title":"MedComm"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"102499","DOI":"10.1016\/j.cbpa.2024.102499","article-title":"Rational design of lipid nanoparticles: Overcoming physiological barriers for selective intracellular mRNA delivery","volume":"81","author":"Zhao","year":"2024","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7233","DOI":"10.1038\/s41467-021-27493-0","article-title":"An ionizable lipid toolbox for RNA delivery","volume":"12","author":"Han","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jconrel.2024.08.030","article-title":"Enhancing RNA-lipid nanoparticle delivery: Organ- and cell-specificity and barcoding strategies","volume":"375","author":"Wei","year":"2024","journal-title":"J. Control. Release"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","article-title":"A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates","volume":"26","author":"Sabnis","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/mt.2013.124","article-title":"Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics","volume":"21","author":"Maier","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.3762\/bjnano.16.133","article-title":"PEGylated lipids in lipid nanoparticle delivery dynamics and therapeutic innovation","volume":"16","author":"Gao","year":"2025","journal-title":"Beilstein J. Nanotechnol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1038\/mtna.2013.66","article-title":"Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles","volume":"2","author":"Mui","year":"2013","journal-title":"Mol. Ther.\u2014Nucleic Acids"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jconrel.2010.01.036","article-title":"Endocytosis of nanomedicines","volume":"145","author":"Sahay","year":"2010","journal-title":"J. Control. Release"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nbt.2612","article-title":"Image-based analysis of lipid nanoparticle\u2013mediated siRNA delivery, intracellular trafficking and endosomal escape","volume":"31","author":"Gilleron","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e202400481","DOI":"10.1002\/cbic.202400481","article-title":"In Vivo Delivery Processes and Development Strategies of Lipid Nanoparticles","volume":"25","author":"Cheng","year":"2024","journal-title":"ChemBioChem"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7300","DOI":"10.1021\/acs.nanolett.5b02497","article-title":"Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs","volume":"15","author":"Kauffman","year":"2015","journal-title":"Nano Lett."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","article-title":"Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines","volume":"15","author":"Hassett","year":"2019","journal-title":"Mol. Ther.\u2014Nucleic Acids"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s13346-023-01402-y","article-title":"Inhalable dry powder product (DPP) of mRNA lipid nanoparticles (LNPs) for pulmonary delivery","volume":"14","author":"Sarode","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1021\/acsnanoscienceau.2c00062","article-title":"Recent Advances in Site-Specific Lipid Nanoparticles for mRNA Delivery","volume":"3","author":"Xu","year":"2023","journal-title":"ACS Nanosci. Au"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.xphs.2023.11.023","article-title":"Factors Affecting Stability of RNA\u2014Temperature, Length, Concentration, pH, and Buffering Species","volume":"113","author":"Chheda","year":"2024","journal-title":"J. Pharm. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"102774","DOI":"10.1016\/j.mtbio.2026.102774","article-title":"Programmable lipid nanoparticles for RNA therapeutics: Design principles and clinical translation","volume":"37","author":"Mirzaee","year":"2026","journal-title":"Mater. Today Bio"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Wang, J., Ding, Y., Chong, K., Cui, M., Cao, Z., Tang, C., Tian, Z., Hu, Y., Zhao, Y., and Jiang, S. (2024). Recent Advances in Lipid Nanoparticles and Their Safety Concerns for mRNA Delivery. Vaccines, 12.","DOI":"10.3390\/vaccines12101148"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1038\/s41598-024-52685-1","article-title":"A careful look at lipid nanoparticle characterization: Analysis of benchmark formulations for encapsulation of RNA cargo size gradient","volume":"14","author":"Schober","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nnano.2014.84","article-title":"In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight","volume":"9","author":"Dahlman","year":"2014","journal-title":"Nat. Nanotechnol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jcis.2020.12.060","article-title":"Synthetic ionizable aminolipids induce a pH dependent inverse hexagonal to bicontinuous cubic lyotropic liquid crystalline phase transition in monoolein nanoparticles","volume":"589","author":"Rajesh","year":"2021","journal-title":"J. Colloid Interface Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"101436","DOI":"10.1016\/j.omtm.2025.101436","article-title":"Why do lipid nanoparticles target the liver? Understanding of biodistribution and liver-specific tropism","volume":"33","author":"Bremmell","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"122896","DOI":"10.1016\/j.biomaterials.2024.122896","article-title":"Poly(\u03b2-amino ester) polymer library with monomer variation for mRNA delivery","volume":"314","author":"Kim","year":"2025","journal-title":"Biomaterials"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41541-023-00766-z","article-title":"Polyethylene glycol (PEG)-associated immune responses triggered by clinically relevant lipid nanoparticles in rats","volume":"8","author":"Wang","year":"2023","journal-title":"npj Vaccines"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.mattod.2025.11.032","article-title":"Biodegradable lipid nanoparticles for genome editing in the brain via intrathecal administration","volume":"92","author":"Dong","year":"2026","journal-title":"Mater. Today"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.matt.2022.03.006","article-title":"The roles of polymers in mRNA delivery","volume":"5","author":"Huang","year":"2022","journal-title":"Matter"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e2409572122","DOI":"10.1073\/pnas.2409572122","article-title":"Rational design and modular synthesis of biodegradable ionizable lipids via the Passerini reaction for mRNA delivery","volume":"122","author":"Xu","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Han, X., Xu, Y., Ricciardi, A., Xu, J., Palanki, R., Chowdhary, V., Xue, L., Gong, N., Alameh, M.-G., and Peranteau, W.H. (2025). Plug-and-play assembly of biodegradable ionizable lipids for potent mRNA delivery and gene editing in vivo. bioRxiv.","DOI":"10.1101\/2025.02.25.640222"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"24302","DOI":"10.1021\/jacs.3c09143","article-title":"Modular Design of Biodegradable Ionizable Lipids for Improved mRNA Delivery and Precise Cancer Metastasis Delineation In Vivo","volume":"145","author":"Chen","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"126554","DOI":"10.1016\/j.ijpharm.2026.126554","article-title":"Alkaline phosphatase-triggered charge converting lipid nanoparticles: An innovative approach for oral nucleic acid delivery","volume":"690","author":"Polidori","year":"2026","journal-title":"Int. J. Pharm."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1007\/s13346-024-01538-5","article-title":"Design of charge converting lipid nanoparticles via a microfluidic coating technique","volume":"14","author":"Haddadzadegan","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.31635\/ccschem.023.202303542","article-title":"Engineering Cell-Selective Charge-Altering Lipid Nanoparticles for Efficient siRNA Delivery in Vivo","volume":"6","author":"Yang","year":"2024","journal-title":"CCS Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e04830","DOI":"10.1002\/adma.202504830","article-title":"Dendrimers Improve Apolipoprotein Nanoparticle mRNA Delivery to Immune Cells","volume":"38","author":"Trines","year":"2026","journal-title":"Adv. Mater."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1038\/s41467-025-56448-y","article-title":"Targeted delivery of TGF-\u03b2 mRNA to murine lung parenchyma using one-component ionizable amphiphilic Janus Dendrimers","volume":"16","author":"Meshanni","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2414991","DOI":"10.1002\/adma.202414991","article-title":"Highly Branched Poly(\u03b2-amino ester)s for Efficient mRNA Delivery and Nebulization Treatment of Silicosis","volume":"37","author":"Yong","year":"2025","journal-title":"Adv. Mater."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Pilipenko, I., Korovkina, O., Gubina, N., Ekimova, V., Ishutinova, A., Korzhikova-Vlakh, E., Tennikova, T., and Korzhikov-Vlakh, V. (2022). Random Copolymers of Lysine and Isoleucine for Efficient mRNA Delivery. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23105363"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"8261","DOI":"10.1021\/acsabm.4c00983","article-title":"Efficacy of Chitosan-N-Arginine Chitosomes in mRNA Delivery and Cell Viability Enhancement","volume":"7","author":"Garcia","year":"2024","journal-title":"ACS Appl. Bio Mater."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Liu, H., Deng, Y., Li, J., Lin, W., Liu, C., Yang, X., Zhou, Z., and Jiang, Y. (2025). Ginger-derived exosome-like nanoparticles: A representative of plant-based natural nanostructured drug delivery system. Front. Bioeng. Biotechnol., 13.","DOI":"10.3389\/fbioe.2025.1569889"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e2304966120","DOI":"10.1073\/pnas.2304966120","article-title":"Inhaled mRNA nanoparticles dual-targeting cancer cells and macrophages in the lung for effective transfection","volume":"120","author":"Tang","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nbt.2614","article-title":"Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling","volume":"31","author":"Sahay","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1186\/s12951-024-02634-x","article-title":"Exosome for mRNA delivery: Strategies and therapeutic applications","volume":"22","author":"Iqbal","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"101","DOI":"10.18609\/nai.2024.015","article-title":"Challenges and advances of the stability of mRNA delivery therapeutics","volume":"1","author":"Zhai","year":"2024","journal-title":"Nucleic Acid Insights"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"20019","DOI":"10.1038\/srep20019","article-title":"Intrathecal delivery of frataxin mRNA encapsulated in lipid nanoparticles to dorsal root ganglia as a potential therapeutic for Friedreich\u2019s ataxia","volume":"6","author":"Nabhan","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"102313","DOI":"10.1016\/j.omtn.2024.102313","article-title":"Advancements and challenges in mRNA and ribonucleoprotein-based therapies: From delivery systems to clinical applications","volume":"35","author":"Eftekhari","year":"2024","journal-title":"Mol. Ther.\u2014Nucleic Acids"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2202688","DOI":"10.1002\/adhm.202202688","article-title":"Polymer-Based mRNA Delivery Strategies for Advanced Therapies","volume":"12","author":"Yang","year":"2023","journal-title":"Adv. Healthc. Mater."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"123541","DOI":"10.1016\/j.biomaterials.2025.123541","article-title":"Biodegradable polymers with tertiary amines enhance mRNA delivery of lipid nanoparticles via improved endosomal escape","volume":"324","author":"Zhao","year":"2026","journal-title":"Biomaterials"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2402715","DOI":"10.1002\/smll.202402715","article-title":"Delivery of mRNA Using Biomimetic Vectors: Progress and Challenges","volume":"20","author":"Yin","year":"2024","journal-title":"Small"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/s12276-024-01201-6","article-title":"Recent advances in extracellular vesicles for therapeutic cargo delivery","volume":"56","author":"Kim","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e1384","DOI":"10.1002\/ctm2.1384","article-title":"mRNA vaccine in cancer therapy: Current advance and future outlook","volume":"13","author":"Li","year":"2023","journal-title":"Clin. Transl. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"105543","DOI":"10.1016\/j.ebiom.2024.105543","article-title":"Nanostructured lipid carriers based mRNA vaccine leads to a T cell\u2013inflamed tumour microenvironment favourable for improving PD-1\/PD-L1 blocking therapy and long-term immunity in a cold tumour model","volume":"112","author":"Fournier","year":"2025","journal-title":"eBioMedicine"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41421-024-00743-3","article-title":"The guided fire from within: Intratumoral administration of mRNA-based vaccines to mobilize memory immunity and direct immune responses against pathogen to target solid tumors","volume":"10","author":"Li","year":"2025","journal-title":"Cell Discov."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e2301606120","DOI":"10.1073\/pnas.2301606120","article-title":"Biodegradable lipophilic polymeric mRNA nanoparticles for ligand-free targeting of splenic dendritic cells for cancer vaccination","volume":"120","author":"Karlsson","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.jacc.2022.11.005","article-title":"The Global Burden of Cardiovascular Diseases and Risk","volume":"80","author":"Vaduganathan","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","article-title":"Global, regional, and national burden of disorders affecting the nervous system, 1990\u20132021: A systematic analysis for the Global Burden of Disease Study 2021","volume":"23","author":"Steinmetz","year":"2024","journal-title":"Lancet Neurol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jchf.2023.09.015","article-title":"Applications of Gene Therapy in Cardiomyopathies","volume":"12","author":"Argiro","year":"2024","journal-title":"JACC Heart Fail."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s40265-018-0983-6","article-title":"Patisiran: First Global Approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/nbt.2682","article-title":"Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction","volume":"31","author":"Zangi","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jconrel.2022.01.027","article-title":"Delivery of modified mRNA to damaged myocardium by systemic administration of lipid nanoparticles","volume":"343","author":"Evers","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.7150\/ijbs.21635","article-title":"Risk Factors and Preventions of Breast Cancer","volume":"13","author":"Sun","year":"2017","journal-title":"Int. J. Biol. Sci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1801570","DOI":"10.1002\/adma.201801570","article-title":"Unlockable Nanocomplexes with Self-Accelerating Nucleic Acid Release for Effective Staged Gene Therapy of Cardiovascular Diseases","volume":"30","author":"Nie","year":"2018","journal-title":"Adv. Mater."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/mt.2015.193","article-title":"Myocardial Delivery of Lipidoid Nanoparticle Carrying modRNA Induces Rapid and Transient Expression","volume":"24","author":"Turnbull","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ymthe.2022.11.017","article-title":"Direct intramyocardial injection of VEGF mRNA in patients undergoing coronary artery bypass grafting","volume":"31","author":"Anttila","year":"2023","journal-title":"Mol. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"eaat9365","DOI":"10.1126\/sciadv.aat9365","article-title":"Cardiac cell\u2013integrated microneedle patch for treating myocardial infarction","volume":"4","author":"Tang","year":"2018","journal-title":"Sci. Adv."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41392-024-02002-z","article-title":"Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41573-021-00355-6","article-title":"VEGFA mRNA for regenerative treatment of heart failure","volume":"21","author":"Bergenhem","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"6058","DOI":"10.1038\/s41467-024-50312-1","article-title":"Inhalable cardiac targeting peptide modified nanomedicine prevents pressure overload heart failure in male mice","volume":"15","author":"Weng","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1126\/science.aay3638","article-title":"A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis","volume":"371","author":"Krienke","year":"2021","journal-title":"Science"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1902575","DOI":"10.1002\/adma.201902575","article-title":"Fast and Efficient CRISPR\/Cas9 Genome Editing In Vivo Enabled by Bioreducible Lipid and Messenger RNA Nanoparticles","volume":"31","author":"Liu","year":"2019","journal-title":"Adv. Mater."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/MED.0000000000000857","article-title":"APOC3 siRNA and ASO therapy for dyslipidemia","volume":"31","author":"Chebli","year":"2024","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1038\/s41467-020-16439-7","article-title":"Treatment of atherosclerosis by macrophage-biomimetic nanoparticles via targeted pharmacotherapy and sequestration of proinflammatory cytokines","volume":"11","author":"Gao","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"17721","DOI":"10.1021\/acsnano.3c00958","article-title":"Modulating Plaque Inflammation via Targeted mRNA Nanoparticles for the Treatment of Atherosclerosis","volume":"17","author":"Gao","year":"2023","journal-title":"ACS Nano"},{"key":"ref_93","first-page":"387","article-title":"In utero delivery of mRNA to the heart, diaphragm and muscle with lipid nanoparticles","volume":"25","author":"Gao","year":"2023","journal-title":"Bioact. Mater."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/rmv.2131","article-title":"An overview of the immune mechanisms of viral myocarditis","volume":"30","author":"Lasrado","year":"2020","journal-title":"Rev. Med. Virol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.1038\/ncomms6515","article-title":"Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice","volume":"5","author":"Mearini","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/cr.2016.101","article-title":"Genome editing with CRISPR\/Cas9 in postnatal mice corrects PRKAG2 cardiac syndrome","volume":"26","author":"Xie","year":"2016","journal-title":"Cell Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jacbts.2022.04.002","article-title":"Cardiac Transduction in Mini-Pigs After Low-Dose Retrograde Coronary Sinus Infusion of AAV9-BAG3","volume":"7","author":"Myers","year":"2022","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_98","first-page":"e202304","article-title":"Lessons from the first-in-human in vivo CRISPR\/Cas9 editing of the TTR gene by NTLA-2001 trial in patients with transthyretin amyloidosis with cardiomyopathy","volume":"2023","author":"Kotit","year":"2023","journal-title":"Glob. Cardiol. Sci. Pract."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jconrel.2024.03.056","article-title":"mRNA therapies: Pioneering a new era in rare genetic disease treatment","volume":"369","author":"Shen","year":"2024","journal-title":"J. Control. Release"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/s41587-022-01491-z","article-title":"Unlocking the promise of mRNA therapeutics","volume":"40","author":"Rohner","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","article-title":"mRNA-based therapeutics: Powerful and versatile tools to combat diseases","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Baptista, B., Carapito, R., Laroui, N., Pichon, C., and Sousa, F. (2021). mRNA, a Revolution in Biomedicine. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13122090"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jconrel.2021.12.027","article-title":"Added to pre-existing inflammation, mRNA-lipid nanoparticles induce inflammation exacerbation (IE)","volume":"344","author":"Parhiz","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41573-023-00859-3","article-title":"Strategies to reduce the risks of mRNA drug and vaccine toxicity","volume":"23","author":"Bitounis","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jconrel.2017.09.044","article-title":"Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus","volume":"266","author":"Sato","year":"2017","journal-title":"J. Control. Release"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijpharm.2007.11.005","article-title":"Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes","volume":"354","author":"Ishida","year":"2008","journal-title":"Int. J. Pharm."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Yadati, T., Houben, T., Bitorina, A., and Shiri-Sverdlov, R. (2020). The Ins and Outs of Cathepsins: Physiological Function and Role in Disease Management. Cells, 9.","DOI":"10.3390\/cells9071679"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41419-023-05786-0","article-title":"Cathepsin B in programmed cell death machinery: Mechanisms of execution and regulatory pathways","volume":"14","author":"Xie","year":"2023","journal-title":"Cell Death Dis."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Cheng, F., Wang, Y., Bai, Y., Liang, Z., Mao, Q., Liu, D., Wu, X., and Xu, M. (2023). Research Advances on the Stability of mRNA Vaccines. Viruses, 15.","DOI":"10.3390\/v15030668"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s12276-023-00999-x","article-title":"Knife\u2019s edge: Balancing immunogenicity and reactogenicity in mRNA vaccines","volume":"55","author":"Lee","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.immuni.2022.05.007","article-title":"Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses","volume":"55","author":"Alameh","year":"2022","journal-title":"Immunity"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41551-023-01082-6","article-title":"Enhancing the immunogenicity of lipid-nanoparticle mRNA vaccines by adjuvanting the ionizable lipid and the mRNA","volume":"9","author":"Li","year":"2023","journal-title":"Nat. Biomed. Eng."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1016\/j.biomaterials.2010.02.049","article-title":"Effects of cleavable PEG-cholesterol derivatives on the accelerated blood clearance of PEGylated liposomes","volume":"31","author":"Xu","year":"2010","journal-title":"Biomaterials"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jconrel.2021.12.008","article-title":"The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency","volume":"342","author":"Anderluzzi","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2635868","DOI":"10.1080\/21645515.2026.2635868","article-title":"Current landscape of clinical trials for mRNA-based therapeutics","volume":"22","author":"Li","year":"2026","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1021\/acsnano.4c12965","article-title":"Robust, Scalable Microfluidic Manufacturing of RNA\u2013Lipid Nanoparticles Using Immobilized Antifouling Lubricant Coating","volume":"19","author":"Hwang","year":"2025","journal-title":"ACS Nano"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e2303567120","DOI":"10.1073\/pnas.2303567120","article-title":"Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines","volume":"120","author":"Shepherd","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1038\/s41596-025-01174-4","article-title":"The design, manufacture and LNP formulation of mRNA for research use","volume":"20","author":"Leighton","year":"2025","journal-title":"Nat. Protoc."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1039\/D4PY00206G","article-title":"Rational design of polymer-based mRNA delivery systems for cancer treatment","volume":"15","author":"Wan","year":"2024","journal-title":"Polym. Chem."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Youssef, M., Hitti, C., Puppin Chaves Fulber, J., and Kamen, A.A. (2023). Enabling mRNA Therapeutics: Current Landscape and Challenges in Manufacturing. Biomolecules, 13.","DOI":"10.3390\/biom13101497"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Yousefi Adlsadabad, S., Hanrahan, J.W., and Kakkar, A. (2024). mRNA Delivery: Challenges and Advances through Polymeric Soft Nanoparticles. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25031739"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"(2025). The untapped potential of mRNA\u2013lipid nanoparticles. Nat. Rev. Bioeng., 3, 715.","DOI":"10.1038\/s44222-025-00362-x"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.1038\/s41467-021-26926-0","article-title":"A novel mechanism for the loss of mRNA activity in lipid nanoparticle delivery systems","volume":"12","author":"Packer","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s13346-015-0220-8","article-title":"Influence of cholesterol on liposome stability and on in vitro drug release","volume":"5","author":"Briuglia","year":"2015","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejpb.2013.05.019","article-title":"Recent advances and further challenges in lyophilization","volume":"85","author":"Kasper","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.ejps.2010.08.010","article-title":"Long-term stability of sterically stabilized liposomes by freezing and freeze-drying: Effects of cryoprotectants on structure","volume":"41","author":"Stark","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA","volume":"23","author":"Buckstein","year":"2005","journal-title":"Immunity"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"10604","DOI":"10.1093\/nar\/gkab764","article-title":"Theoretical basis for stabilizing messenger RNA through secondary structure design","volume":"49","author":"Kim","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jconrel.2022.11.042","article-title":"Hybrid core-shell particles for mRNA systemic delivery","volume":"353","author":"Andretto","year":"2023","journal-title":"J. Control. Release"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41392-021-00634-z","article-title":"A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity","volume":"6","author":"Yang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.omtm.2022.03.009","article-title":"A flexible, thermostable nanostructured lipid carrier platform for RNA vaccine delivery","volume":"25","author":"Gerhardt","year":"2022","journal-title":"Mol. Ther.\u2014Methods Clin. Dev."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Siewert, C.D., Haas, H., Cornet, V., Nogueira, S.S., Nawroth, T., Uebbing, L., Ziller, A., Al-Gousous, J., Radulescu, A., and Schroer, M.A. (2020). Hybrid Biopolymer and Lipid Nanoparticles with Improved Transfection Efficacy for mRNA. Cells, 9.","DOI":"10.3390\/cells9092034"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"102721","DOI":"10.1016\/j.omtn.2025.102721","article-title":"mRNA therapeutics: Transforming medicine through innovation in design, delivery, and disease treatment","volume":"36","author":"Ige","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/5\/663\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T04:12:56Z","timestamp":1777176776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/5\/663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":133,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["ph19050663"],"URL":"https:\/\/doi.org\/10.3390\/ph19050663","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]}}}